SRR5088816
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- MYC_TARGETS_V2+0.500
- ALLOGRAFT_REJECTION+0.400
- HEDGEHOG_SIGNALING+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- MTORC1_SIGNALING+0.400
Top 10 suppressed
- KRAS_SIGNALING_DN-0.200
- MYOGENESIS-0.200
- BILE_ACID_METABOLISM-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- UV_RESPONSE_DN-0.100
- WNT_BETA_CATENIN_SIGNALING-0.100
- ADIPOGENESIS+0.000
- ANGIOGENESIS+0.000
- APICAL_JUNCTION+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.890 |
| 2 | BS_4QW2S1Q8 | high-grade glioma | — | 0.885 |
| 3 | SRR1313147 | — | E | 0.878 |
| 4 | DRR168585 | — | — | 0.876 |
| 5 | TCGA-CV-7434-01A-11R-2132-07 | — | — | 0.863 |
| 6 | 20130321.TNBC | — | C | 0.858 |
| 7 | SJEPD030791_D1.RNA-Seq | EPN | Supratentorial EPN | 0.857 |
| 8 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.855 |
| 9 | TCGA-XF-AAN5-01A-11R-A42T-07 | — | — | 0.851 |
| 10 | MNG766 | — | — | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |